Skip to content

The effect of Ondansetron in children suffered from Gastroenteritis and recurrent vomiting

The effect of Ondansetron on decreasing hospitalization rate in children with gustroenteritis and recurrent vomiting

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014090719077N1
Enrollment
200
Registered
2014-11-22
Start date
2014-10-16
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroenteritis. Gastroenteritis

Interventions

Intervention 1: Intervention group: Injection of Ondansetron , 0.15 mg per kg . Single dose with serum normal saline will be injected.AMP DEMITRON ( Ondansetron) 4MG/2ML that vials are manufactured
Treatment - Drugs
Intervention group: Injection of Ondansetron , 0.15 mg per kg . Single dose with serum normal saline will be injected.AMP DEMITRON ( Ondansetron) 4MG/2ML that vials are manufactured by Tehran- Chemi
Control group: Injection of1 mg per KG of Metoclopramide single dose with serum Normal Saline. METOCLOPRAMIDE DAROUPAKHSH 10MG/2ML AMP

Sponsors

Vice chancellor for research, Qazvin University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Months to 6 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with the evidence of viral GE that recurrent vomiting are the only indication of referring them to hospital and the time of their referral to the hospital is not more than 48 hours after the beginning of the symptoms exclusion criteria: Other cases with other causes (bacterial GE, protozoan GE, etc.) or vomiting secondary to other diseases and patients with symptoms prolonger than 48 hours

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Whether the patients have any need to be returned to hospital because of recurrence of vomiting or not. Timepoint: 1 week. Method of measurement: percent of patients with hospitalization.

Secondary

MeasureTime frame
-. Timepoint: -. Method of measurement: -.

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026